SVETLANA VIKHROVA: NEW CANCER RESEARCH TECHNIQUES MAY GIVE SURGEONS EXPANDED CAPABILITIES
Posted Dec 11 2012 3:52pm
New advances in cancer research are being made by the day, if not by the hour. Svetlana Vikhrova, a Russian project manager for implementation of cancer diagnostics innovations is highly familiar with the vital field of science and innovation, which has the lofty goal of helping critically ill patients find viable solutions.
Many leading experts from all around the world, such as Svetlana Vikhrova, spend the bulk of their careers supporting innovative cancer research and groundbreaking techniques that can be used in the early diagnosis of diseases such as cancer and bacterial infection. These techniques include the use of image-guided surgery, which gives surgeons the ability to receive clear and precise visual information about cancer margins during surgery.
Cancer research conducted by leading scientists, educators, medical professionals, and biologists has found that naturally fluorescent proteins may have a revolutionary impact on the field of cancer diagnosis. How? By enabling what was formerly opaque to become transparent, what was formerly hidden to become visible.
Fluorescent proteins allow surgeons to see, in real-time, important aspects of cancer in living organisms. For breast cancer and colorectal cancer patients, this technology is critical to early diagnosis and possible options for non-invasive treatments. This is because fluorescent proteins can be used to “color code” cancer cells in vivo. Therefore, cancerous tumors can more precisely be distinguished from healthy tissue. Fluorescence imaging of tumor growth and metastasis can be attained, in real-time, with high levels of specificity, and high resolution in vivo without the need for invasive techniques or pricey imaging equipment. This is precisely why the support of leading managers like Svetlana Vikhrova is so crucial to cancer research, as she and others in this field are dedicated to finding innovative solutions.
In vivo cellular imaging using fluorescent proteins thus represents an advantage for the patients who are not subjected to continuous biopsies, while research institutions and companies across the world, from Switzerland’s Intrace Medical to Moores Cancer Center at the University of California San Diego, are investigating how the use of these probes can further advance cancer research, diagnosis, and treatment options.